Study: Monoclonal Antibodies Massively Reduced Risk of Hospitalization Among High-Risk COVID-Positive Individuals

Treatment with two monoclonal antibodies lowers the odds of hospitalization for high-risk COVID-19 patients with mild to moderate illness, according to a new study.

“Our conclusion overall at this point is that monoclonal antibodies are an important option in treatment to reduce the impact of COVID-19 in high-risk patients,” said senior author Dr. Raymund Razonable, an infectious diseases specialist at the Mayo Clinic in Rochester, Minn.

The combination of casirivimab and imdevimab has emergency use authorization from the U.S. Food and Drug Administration.

The study included 696 COVID-19 patients treated with the combo at the Mayo Clinic between December 2020 and early April 2021, and an equal number of patients who didn’t receive it. . .

Overall, patients who received the combo therapy had a 60% to 70% lower risk of hospitalization than untreated patients, the findings showed. (Read more from “Study: Monoclonal Antibodies Massively Reduced Risk of Hospitalization Among High-Risk COVID-Positive Individuals” HERE)

Delete Facebook, Delete Twitter, Follow Restoring Liberty and Joe Miller at gab HERE.